MA33060B1 - Formulations galéniques de composés organiques - Google Patents

Formulations galéniques de composés organiques

Info

Publication number
MA33060B1
MA33060B1 MA34114A MA34114A MA33060B1 MA 33060 B1 MA33060 B1 MA 33060B1 MA 34114 A MA34114 A MA 34114A MA 34114 A MA34114 A MA 34114A MA 33060 B1 MA33060 B1 MA 33060B1
Authority
MA
Morocco
Prior art keywords
tablet
central portion
pharmacy
capsules
organic compounds
Prior art date
Application number
MA34114A
Other languages
Arabic (ar)
English (en)
Inventor
Sabine Desset-Brèthes
Stefan Hirsch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40770648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33060(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33060B1 publication Critical patent/MA33060B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une forme de dosage unitaire solide pour administration orale sous la forme d'un comprimé, doté d'une partie centrale et d'un enrobage externe. Ladite partie centrale dudit comprimé comprend une quantité thérapeutiquement efficace d'Aliskiren, ou un sel pharmaceutiquement acceptable de celui-ci, et l'enrobage externe se présente sous la forme d'un revêtement de film qui possède des propriétés de masquage de goût et/ou une fonctionnalité de libération contrôlée. De préférence, le comprimé avec partie centrale fait partie d'un système multiparticulaire, et est en particulier un mini-comprimé. La forme de dosage oral solide est particulièrement adaptée à un usage pédiatrique.
MA34114A 2009-01-28 2010-01-27 Formulations galéniques de composés organiques MA33060B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151496 2009-01-28
PCT/EP2010/050886 WO2010086312A1 (fr) 2009-01-28 2010-01-27 Formulations galéniques de composés organiques

Publications (1)

Publication Number Publication Date
MA33060B1 true MA33060B1 (fr) 2012-02-01

Family

ID=40770648

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34114A MA33060B1 (fr) 2009-01-28 2010-01-27 Formulations galéniques de composés organiques

Country Status (27)

Country Link
US (1) US20110287100A1 (fr)
EP (1) EP2391345B1 (fr)
JP (1) JP2012516299A (fr)
KR (1) KR20110117199A (fr)
CN (1) CN102300558A (fr)
AR (1) AR075179A1 (fr)
AU (1) AU2010209787B2 (fr)
BR (1) BRPI1007452A2 (fr)
CA (1) CA2749531A1 (fr)
CL (1) CL2011001817A1 (fr)
CO (1) CO6400184A2 (fr)
EC (1) ECSP11011289A (fr)
ES (1) ES2525648T3 (fr)
IL (1) IL213918A0 (fr)
MA (1) MA33060B1 (fr)
MX (1) MX2011007779A (fr)
MY (1) MY153852A (fr)
NZ (1) NZ593622A (fr)
PE (1) PE20110943A1 (fr)
PL (1) PL2391345T3 (fr)
PT (1) PT2391345E (fr)
RU (1) RU2535090C2 (fr)
SG (1) SG172226A1 (fr)
TN (1) TN2011000307A1 (fr)
TW (1) TWI468191B (fr)
WO (1) WO2010086312A1 (fr)
ZA (1) ZA201104489B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5822758B2 (ja) * 2011-03-02 2015-11-24 第一三共ヘルスケア株式会社 速溶性防湿フィルムコーティング製剤及びその製造方法
EP2596802A1 (fr) * 2011-11-23 2013-05-29 PLS-Design GmbH Composition pharmaceutique pour le traitement des réactions allergiques
HRP20250913T1 (hr) * 2016-02-03 2025-09-26 Novartis Ag Nova upotreba kombinacije sakubitrila i valsartana
US12171878B2 (en) 2018-08-10 2024-12-24 Kissei Pharmaceutical Co., Ltd. Sucroferric oxyhydroxide-containing granules and pharmaceutical composition
GB2585413B (en) 2019-02-22 2023-04-26 Catalent Uk Swindon Zydis Ltd Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
WO2020169989A1 (fr) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Réduction au minimum de l'agglomération, de l'aération et préservation du revêtement de compositions pharmaceutiques comprenant de l'ibuprofène
TWI849062B (zh) 2019-02-22 2024-07-21 英商康泰倫特英國斯文敦載迪斯有限公司 保存水性懸浮液中以無溶劑混合方法製備的功能性塗覆之活性醫藥成份微粒
CN113507923B (zh) 2019-02-22 2024-03-26 康特伦英国斯温顿捷迪斯有限公司 在线混合期间混悬液的曝气最小化
WO2021011538A1 (fr) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Formes galéniques capsules, leurs procédés de préparation et leurs procédés d'utilisation
BR112023001716A2 (pt) 2020-07-31 2023-04-04 Catalent Uk Swindon Zydis Ltd Composições farmacêuticas compreendendo api revestido
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
WO2025072751A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
TW202523280A (zh) * 2023-11-17 2025-06-16 日商第一三共健康事業股份有限公司 固體製劑
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
WO2004100871A2 (fr) * 2003-05-09 2004-11-25 Pharmacia Corporation Combinaison d'un antagoniste du recepteur de l'aldosterone et d'un inhibiteur de renine
AR048431A1 (es) 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
WO2005105054A1 (fr) * 2004-04-15 2005-11-10 Dr. Reddy's Laboratories Ltd. Forme de dosage ayant une stabilité polymorphique
EP2248520A3 (fr) * 2004-10-08 2010-11-17 Novartis AG Utilisation d'inhibiteurs de rénine pour la prévention ou le traitement du dysfonctionnement diastolique ou de la cardiopathie diastolique
WO2009045796A1 (fr) * 2007-09-28 2009-04-09 Novartis Ag Combinaison pharmaceutique d'aliskirène et de valsartane

Also Published As

Publication number Publication date
ES2525648T3 (es) 2014-12-26
CL2011001817A1 (es) 2012-01-13
PL2391345T3 (pl) 2015-03-31
JP2012516299A (ja) 2012-07-19
TN2011000307A1 (en) 2012-12-17
CN102300558A (zh) 2011-12-28
TW201038300A (en) 2010-11-01
AR075179A1 (es) 2011-03-16
PT2391345E (pt) 2014-12-03
AU2010209787B2 (en) 2013-06-06
EP2391345A1 (fr) 2011-12-07
TWI468191B (zh) 2015-01-11
IL213918A0 (en) 2011-07-31
NZ593622A (en) 2013-12-20
MY153852A (en) 2015-03-31
US20110287100A1 (en) 2011-11-24
ECSP11011289A (es) 2011-09-30
PE20110943A1 (es) 2012-01-22
BRPI1007452A2 (pt) 2016-02-16
MX2011007779A (es) 2011-08-12
CO6400184A2 (es) 2012-03-15
WO2010086312A1 (fr) 2010-08-05
KR20110117199A (ko) 2011-10-26
AU2010209787A1 (en) 2011-07-14
SG172226A1 (en) 2011-07-28
CA2749531A1 (fr) 2010-08-05
EP2391345B1 (fr) 2014-09-03
RU2011135417A (ru) 2013-03-10
RU2535090C2 (ru) 2014-12-10
ZA201104489B (en) 2012-02-29
HK1161125A1 (en) 2012-08-24

Similar Documents

Publication Publication Date Title
MA30807B1 (fr) Compositions pharmaceutiques.
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
EP2248519A3 (fr) Formes galéniques de film non mucoadhésifs
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MY153852A (en) Galenic formulations of organic compounds
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
MA31396B1 (fr) Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes
MY156822A (en) Indole derivatives as s1p1 receptor agonists
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
WO2007095091A3 (fr) Administration orale d'agents thérapeutiques utilisant des agonistes à jonctions serrées
MA31706B1 (fr) Formulations galéniques de composés organiques
EP2548552A3 (fr) Ensemble de titration pour 1-amino-alkylcyclohexanes
TNSN08428A1 (fr) NOUVELLE FORME d'ADMINISTRATION DU RACECADOTRIL
BR112012016460A2 (pt) diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica.
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
TR200102811T2 (tr) Oral uygulama için, tolpersiyon içeren farmasötik preparat.
EP2296654A4 (fr) Dérivés de 8-hydroxyquinoline pour le traitement d'hémopathies malignes
BRPI0817275A2 (pt) Combinação farmacêutica de alisquireno e valsartana
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
EP4487915A3 (fr) Formulations de capsules
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
MA50201B1 (fr) Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
WO2008151811A3 (fr) Procédé de fabrication d'un médicament contenant du trihydrate d'hydrochlorure de vardénafil
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale